| LONZA-BIOSCIENCE-SINGAPORE-PTE-LTD |
LONZA-BIOSCIENCE-SINGAPORE-PTE-LTD |
85%
|
rs, including the failure to produce sufficient quantities and the inability to produce cells that are equivalent in physical and therapeutic properties as compared to the products produced using our… |
| UNITED-STATES-THE-GROUP |
UNITED-STATES-THE-GROUP |
85%
|
The Group began commercializing Ryoncil ® in the United States for the treatment of pediatric patients with SR-aGvHD in March 2025. The Group's product revenues consist of sales of Ryoncil ® in the U… |
| EDSA |
Edesa Biotech, Inc. |
72%
|
Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from MESO graph: agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods o… |
| AUSTRALIA-THE-GROUP |
AUSTRALIA-THE-GROUP |
62%
|
nce with International Financial Reporting Standards, as issued by the International Accounting Standards Board and Australian equivalent International Financial Reporting Standards, as issued by the… |
| AUSTRALIA-YES-N-A-MESOBLAST-INC |
AUSTRALIA-YES-N-A-MESOBLAST-INC |
62%
|
ties include the net present value of the following lease payments: • fixed payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payment that are b… |
| AUSTRALIA-YES-N-A-MESOBLAST-UK-LIMITED |
AUSTRALIA-YES-N-A-MESOBLAST-UK-LIMITED |
62%
|
ties include the net present value of the following lease payments: • fixed payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payment that are b… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
. These are the primary components of our business that management monitors and assesses in making decisions about resource allocation and performance evaluation. Further details on financial perform… |
| CENTRAL-ADELAIDE-LOCAL-HEALTH-NETWORK-INCORPORAT |
CENTRAL-ADELAIDE-LOCAL-HEALTH-NETWORK-INCORPORAT |
62%
|
ne 30, 2025 and 2024, together with the changes in those items. Year ended June 30, (in U.S. dollars, in thousands) 2025 2024 $ Change % Change Revenue: Product sales, net 11,263 — 11,263 NM Royalty … |
| CHINA-THE-GROUP |
CHINA-THE-GROUP |
62%
|
agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t… |
| CLASSIFICATION-THE-GROUP |
CLASSIFICATION-THE-GROUP |
62%
|
atement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term and highly liquid investments with original maturities of t… |
| IP-THE-GROUP |
IP-THE-GROUP |
62%
|
agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t… |
| JAPAN-THE-GROUP |
JAPAN-THE-GROUP |
62%
|
ed our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (“EB”) in October 2018, and for neonatal hypoxic ischemic encephalopathy (“HIE”)… |
| LONZA-WALKERSVILLE-INC |
LONZA-WALKERSVILLE-INC |
62%
|
tor the drug’s safety or efficacy. Delays in the REMS approval process could result in delays in the BLA approval process. In addition, as part of the REMS, the FDA could require significant restrict… |
| MEDVET-SCIENCE-PTY-LTD |
MEDVET-SCIENCE-PTY-LTD |
62%
|
ne 30, 2025 and 2024, together with the changes in those items. Year ended June 30, (in U.S. dollars, in thousands) 2025 2024 $ Change % Change Revenue: Product sales, net 11,263 — 11,263 NM Royalty … |
| MESOBLAST-AUSTRALIA-PTY-LTD |
MESOBLAST-AUSTRALIA-PTY-LTD |
62%
|
ties include the net present value of the following lease payments: • fixed payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payment that are b… |
| MESOBLAST-GROUP |
MESOBLAST-GROUP |
62%
|
ne 30, 2025 and 2024, together with the changes in those items. Year ended June 30, (in U.S. dollars, in thousands) 2025 2024 $ Change % Change Revenue: Product sales, net 11,263 — 11,263 NM Royalty … |
| OSIRIS-THERAPEUTICS-INC |
OSIRIS-THERAPEUTICS-INC |
62%
|
cil ® for the treatment of pediatric SR-aGvHD in children 2 months and older. We began commercializing Ryoncil ® in the United States for the treatment of pediatric patients with SR-aGvHD in March 20… |
| SWITZERLAND-NO-SWITZERLAND-MESOBLAST-AUSTRALIA-P |
SWITZERLAND-NO-SWITZERLAND-MESOBLAST-AUSTRALIA-P |
62%
|
ties include the net present value of the following lease payments: • fixed payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payment that are b… |
| TASLY-PHARMACEUTICAL-GROUP |
TASLY-PHARMACEUTICAL-GROUP |
62%
|
agreement to determine if they are distinct. If they are not distinct, they are combined with other promised goods or services to create a bundle of promised goods or services that is distinct. The t… |
| UNITED-KINGDOM-NO-UNITED-KINGDOM-BEICELL-LTD |
UNITED-KINGDOM-NO-UNITED-KINGDOM-BEICELL-LTD |
62%
|
ties include the net present value of the following lease payments: • fixed payments (including in-substance fixed payments), less any lease incentives receivable; • variable lease payment that are b… |
| VWAP-THE-GROUP |
VWAP-THE-GROUP |
62%
|
atement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term and highly liquid investments with original maturities of t… |
